Capital Increase in Genmab as a Result of Employee Warrant Exercise
December 03, 2024 16:35 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
December 03, 2024 07:07 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Genmab to Present at Citi’s Global Healthcare Conference
November 25, 2024 11:06 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will take part in a fireside chat at Citi’s 2024 Global...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
November 21, 2024 14:48 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees...
Genmab Announces Financial Results for the First Nine Months of 2024
November 06, 2024 11:02 ET
|
Genmab A/S
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY®...
Genmab to Present at Jefferies London Healthcare Conference
November 05, 2024 13:11 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony...
Genmab to Showcase Strength and Breadth of Comprehensive Epcoritamab-bysp Development Program at 2024 American Society of Hematology (ASH) Annual Meeting
November 05, 2024 12:00 ET
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 More than 20 abstracts, including four oral presentations, with new clinical data across lines of therapy and subgroups of non-Hodgkin’s lymphoma...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2024
October 15, 2024 06:25 ET
|
Genmab A/S
Company Announcement Net sales of DARZALEX® in the third quarter of 2024 totaled USD 3,016 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) ...
Major Shareholder Announcement
October 04, 2024 13:55 ET
|
Genmab A/S
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; October 4, 2024 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
September 26, 2024 15:17 ET
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; September 26, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 23,954 restricted stock units and 13,915 warrants to employees...